Lukas Aguirre Dávila

ORCID: 0000-0001-6104-9631
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Heart Failure Treatment and Management
  • Cardiovascular Function and Risk Factors
  • Autism Spectrum Disorder Research
  • Hearing, Cochlea, Tinnitus, Genetics
  • Bacterial Infections and Vaccines
  • Hearing Loss and Rehabilitation
  • Craniofacial Disorders and Treatments
  • Obsessive-Compulsive Spectrum Disorders
  • Cleft Lip and Palate Research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Pneumonia and Respiratory Infections
  • SARS-CoV-2 and COVID-19 Research
  • dental development and anomalies
  • Business Process Modeling and Analysis
  • Endometriosis Research and Treatment
  • Data-Driven Disease Surveillance
  • Ovarian function and disorders
  • Cardiac pacing and defibrillation studies
  • Cerebrovascular and Carotid Artery Diseases
  • Cannabis and Cannabinoid Research
  • Eating Disorders and Behaviors
  • Advanced Software Engineering Methodologies
  • Cardiac electrophysiology and arrhythmias
  • Family and Patient Care in Intensive Care Units
  • Medical and Biological Sciences

Morton Plant Hospital
2025

Medizinische Hochschule Hannover
2015-2023

Zimmer Biomet (Germany)
2019-2023

Paul Ehrlich Institut
2020-2023

Society of Interventional Radiology
2017

Universität Hamburg
2016

University Medical Center Hamburg-Eppendorf
2016

Technical University of Munich
2016

Leibniz University Hannover
2010

Abstract The human inner ear has an intricate spiral shape often compared to shells of mollusks, particularly the nautilus shell. It inspired many functional hearing theories. reasons for this complex geometry remain unresolved. We digitized 138 cochleae at microscopic resolution and observed astonishing interindividual variability in shape. A 3D analytical cochlear model was developed that fits analyzed data with high precision. neither matched a proposed function, namely sound focusing...

10.1038/s41598-017-07795-4 article EN cc-by Scientific Reports 2017-08-02

Despite recent advances in the treatment of chronic heart failure (HF), mortality and hospitalizations still remain high. Additional therapies to improve morbidity are urgently needed. The efficacy cardiac glycosides - although regularly used for HF remains unclear. DIGIT-HF was designed demonstrate that digitoxin on top standard care improves patients with a reduced ejection fraction (HFrEF).

10.1002/ejhf.1452 article EN cc-by-nc European Journal of Heart Failure 2019-03-20

Despite development of new and innovative medical therapies, still millions patients with chronic heart failure (HF) reduced ejection fraction and/or atrial fibrillation (AF) are treated cardiac glycosides (overall 122 defined daily dose prescriptions 2013 in Germany).1 Randomized evidence for efficacy this treatment strategy is, however, sparse. For HF (HFrEF), the only randomized controlled outcome trial (RCT) reasonable size is DIG trial.2 Although Trial could not demonstrate a benefit on...

10.1093/eurheartj/ehw577 article EN cc-by-nc European Heart Journal 2016-11-19

Objective The purpose of this study was the diagnostic evaluation hospital anxiety and depression scale total score, its subscale Beck inventory II in adults with congenital heart disease. Methods This cross-sectional evaluated 206 patients disease (mean age 35.3 ± 11.7 years; 58.3% men). Major depressive disorder diagnosed by a structured clinical interview for Diagnostic Statistical Manual Mental Disorders IV severity Montgomery–Åsberg rating scale. Receiver operating characteristics...

10.1177/2047487319865055 article EN European Journal of Preventive Cardiology 2019-07-26

<b>Objective</b> In this retrospective study, we aimed to assess frequency, types, and long-term outcome of neurological disease during acute <i>Mycoplasma pneumoniae</i> (<i>M. pneumoniae</i>) infection in pediatric patients. <b>Materials Methods</b> Medical records patients hospitalized with <i>M. were reviewed. Possible risk factors analyzed by uni- multivariate regression. Patients symptoms followed up expanded disability status score (EDSS) the cognitive problems children adolescents...

10.1055/s-0036-1584325 article EN Neuropediatrics 2016-06-14

Background: Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics tic-specific behavioral therapies. However, due to lack of trained therapists adverse events antipsychotic medication many patients seek alternative treatment options including cannabis. Based on the favorable results obtained from case studies different cannabis-based medicines as well two small randomized controlled...

10.3389/fpsyt.2020.575826 article EN cc-by Frontiers in Psychiatry 2020-11-26

Objective— Intraplaque neovascularization contributes to the progression and rupture of atherosclerotic lesions. Glutamate carboxypeptidase II (GCPII) is strongly expressed by endothelial cells tumor neovasculature plays a major role in hypoxia-induced rodent models benign diseases. We hypothesized that GCPII expression may play intraplaque represent target for imaging The aim this study was determine frequency, pattern, clinical correlates vessel wall uptake 68 Ga-GCPII ligand positron...

10.1161/atvbaha.116.307701 article EN Arteriosclerosis Thrombosis and Vascular Biology 2016-09-09

Transarterial chemoembolization (TACE) is an established treatment for intermediate stage hepatocellular carcinoma (HCC). The aim of this retrospective study was to evaluate the power lesion vascularization criteria based on computed tomography prognosis overall survival before initiation treatment.A total 59 patients with HCC treated TACE as first-line were retrospectively evaluated. procedures performed using doxorubicin, cisplatin, and lipiodol. Response evaluation in solid tumors version...

10.5152/dir.2016.16006 article EN Diagnostic and Interventional Radiology 2017-03-03

The COVID-19 pandemic has manifold impacts on clinical trials. In response, drug regulatory agencies and public health bodies have issued guidance how to assess potential ongoing trials stress the importance of a risk-assessment as pre-requisite for modifications trial conduct. This article presents simulation study impact power an without need unblind data compromise integrity. context CANNA-TICS trial, investigating effect nabiximols reducing total tic score Yale Global Tic Severity Scale...

10.1002/pst.2100 article EN cc-by-nc Pharmaceutical Statistics 2021-02-16

The COVID-19 pandemic triggered an unprecedented research effort to develop vaccines and therapeutics. Urgency dictated that development regulatory assessment were accelerated, while maintaining all standards for quality, safety efficacy. To speed up evaluation the European Medicines Agency (EMA) implemented "rolling reviews" allowing developers submit data as they became available.We discuss clinical trial designs applied statistical approaches in vaccine efficacy trials, focusing on...

10.1080/19466315.2023.2211538 article EN cc-by Statistics in Biopharmaceutical Research 2023-05-10

Abstract Background and study aims Patients with primary sclerosing cholangitis (PSC) require repeated endoscopic retrograde cholangiography (ERC). Our aim was to evaluate whether patients PSC higher doses of sedation during ERC. methods We retrospectively analyzed all undergoing ERC from 2006 2013 who received conscious propofol midazolam. The duration the intervention a potential progression consumption or time by visit number were analyzed. Univariable multivariable analyses performed...

10.1055/s-0043-104858 article EN cc-by-nc-nd Endoscopy International Open 2017-04-01

AIMS OF THE STUDY: To obtain predictions for the course of COVID-19 pandemic in Germany using modified Bateman SIZ model and input variables based on status quo July 2020. predict effect a change tα pandemic. evaluate robustness sensitivity response to parameters. MATERIALS AND METHODS: Start parameters were obtained from observational data published by Robert-Koch-Institute Berlin period June 1 13, The determined changing parameter doubling-time (tα) ± 5% ± 10%. RESULTS: show that small...

10.5414/cp203868 article EN International Journal of Clinical Pharmacology and Therapeutics 2020-08-17
Coming Soon ...